Abiopharma

Avantor® Appoints Simon Dingemans to its Board of Directors

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Johnson & Johnson - Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

Ovid Therapeutics Inc. - Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Natera - Natera Announces Publication of Signatera™Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

Revvity - Revvity to Present at J.P. Morgan Healthcare Conference

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

XWELL Expands Beyond Airports with New Wellness Retail Location in New York City’s Pennsylvania Station

First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D